Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 25 to 36 of 230 entries
Sorted by: Best Match Show Resources per page
New Evidence for .

Evidence-based complementary and alternative medicine : eCAM

Ivanov M, Gašić U, Stojković D, Kostić M, Mišić D, Soković M.
PMID: 34335850
Evid Based Complement Alternat Med. 2021 Jul 22;2021:9961089. doi: 10.1155/2021/9961089. eCollection 2021.

No abstract available.

Cite
Ivanov M, Gašić U, Stojković D, et al. New Evidence for . Evid Based Complement Alternat Med. 2021;2021:9961089doi: 10.1155/2021/9961089.
Ivanov, M., Gašić, U., Stojković, D., Kostić, M., Mišić, D., & Soković, M. (2021). New Evidence for . Evidence-based complementary and alternative medicine : eCAM, 20219961089. https://doi.org/10.1155/2021/9961089
Ivanov, Marija, et al. "New Evidence for ." Evidence-based complementary and alternative medicine : eCAM vol. 2021 (2021): 9961089. doi: https://doi.org/10.1155/2021/9961089
Ivanov M, Gašić U, Stojković D, Kostić M, Mišić D, Soković M. New Evidence for . Evid Based Complement Alternat Med. 2021 Jul 22;2021:9961089. doi: 10.1155/2021/9961089. eCollection 2021. PMID: 34335850; PMCID: PMC8324356.
Copy Download .nbib Format: NLM
[SORD-related hereditary neuropathies].

Medecine sciences : M/S

Fernández-Eulate G, Bruneel A, Stojkovic T.
PMID: 34878391
Med Sci (Paris). 2021 Nov;37:30-31. doi: 10.1051/medsci/2021188. Epub 2021 Dec 08.

Mutations in the SORD gene have recently been identified as a cause of autosomal Charcot-Marie-Tooth disease as well as the underlying defect in some cases of hereditary distal motoneuronopathies. Patients may be amenable to therapies in a near future.

Cite
Fernández-Eulate G, Bruneel A, Stojkovic T. Les neuropathies héréditaires associées au gène SORD. [SORD-related hereditary neuropathies]. Med Sci (Paris). 2021;37:30-31doi: 10.1051/medsci/2021188.
Fernández-Eulate, G., Bruneel, A., & Stojkovic, T. (2021). Les neuropathies héréditaires associées au gène SORD. [SORD-related hereditary neuropathies]. Medecine sciences : M/S, 3730-31. https://doi.org/10.1051/medsci/2021188
Fernández-Eulate, Gorka, et al. "Les neuropathies héréditaires associées au gène SORD." [SORD-related hereditary neuropathies]. Medecine sciences : M/S vol. 37 (2021): 30-31. doi: https://doi.org/10.1051/medsci/2021188
Fernández-Eulate G, Bruneel A, Stojkovic T. Les neuropathies héréditaires associées au gène SORD. [SORD-related hereditary neuropathies]. Med Sci (Paris). 2021 Nov;37:30-31. doi: 10.1051/medsci/2021188. Epub 2021 Dec 08. French. PMID: 34878391.
Copy Download .nbib Format: NLM
Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives.

Cancers

Kwok M, Agathanggelou A, Davies N, Stankovic T.
PMID: 34572908
Cancers (Basel). 2021 Sep 18;13(18). doi: 10.3390/cancers13184681.

The p53 pathway is a desirable therapeutic target, owing to its critical role in the maintenance of genome integrity. This is exemplified in chronic lymphocytic leukemia (CLL), one of the most common adult hematologic malignancies, in which functional loss...

Cite
Kwok M, Agathanggelou A, Davies N, et al. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers (Basel). 2021;13(18)doi: 10.3390/cancers13184681.
Kwok, M., Agathanggelou, A., Davies, N., & Stankovic, T. (2021). Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers, 13(18), . https://doi.org/10.3390/cancers13184681
Kwok, Marwan, et al. "Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives." Cancers vol. 13,18 (2021). doi: https://doi.org/10.3390/cancers13184681
Kwok M, Agathanggelou A, Davies N, Stankovic T. Targeting the p53 Pathway in CLL: State of the Art and Future Perspectives. Cancers (Basel). 2021 Sep 18;13(18). doi: 10.3390/cancers13184681. PMID: 34572908; PMCID: PMC8468925.
Copy Download .nbib Format: NLM
Determinants of diaphragm inspiratory motion, diaphragm thickening, and its performance for predicting respiratory restrictive pattern in Duchenne muscular dystrophy.

Muscle & nerve

Fayssoil A, Nguyen LS, Stojkovic T, Prigent H, Carlier R, Amthor H, Bergounioux J, Zini J, Damez-Fontaine S, Wahbi K, Laforet P, Nicolas G, Behin A, Bassez G, Leturcq F, Ben Yaou R, Mansencal N, Annane D, Lofaso F, Orlikowski D.
PMID: 34618930
Muscle Nerve. 2021 Oct 07; doi: 10.1002/mus.27432. Epub 2021 Oct 07.

INTRODUCTION/AIMS: Respiratory status is a key determinant of prognosis in patients with Duchenne muscular dystrophy (DMD). We aimed to evaluate the determinants of diaphragm ultrasound and its performance in predicting restrictive respiratory patterns in DMD.METHODS: This was a retrospective...

Cite
Fayssoil A, Nguyen LS, Stojkovic T, et al. Determinants of diaphragm inspiratory motion, diaphragm thickening, and its performance for predicting respiratory restrictive pattern in Duchenne muscular dystrophy. Muscle Nerve. 2021;doi: 10.1002/mus.27432.
Fayssoil, A., Nguyen, L. S., Stojkovic, T., Prigent, H., Carlier, R., Amthor, H., Bergounioux, J., Zini, J., Damez-Fontaine, S., Wahbi, K., Laforet, P., Nicolas, G., Behin, A., Bassez, G., Leturcq, F., Ben Yaou, R., Mansencal, N., Annane, D., Lofaso, F., & Orlikowski, D. (2021). Determinants of diaphragm inspiratory motion, diaphragm thickening, and its performance for predicting respiratory restrictive pattern in Duchenne muscular dystrophy. Muscle & nerve, . https://doi.org/10.1002/mus.27432
Fayssoil, Abdallah, et al. "Determinants of diaphragm inspiratory motion, diaphragm thickening, and its performance for predicting respiratory restrictive pattern in Duchenne muscular dystrophy." Muscle & nerve vol. (2021). doi: https://doi.org/10.1002/mus.27432
Fayssoil A, Nguyen LS, Stojkovic T, Prigent H, Carlier R, Amthor H, Bergounioux J, Zini J, Damez-Fontaine S, Wahbi K, Laforet P, Nicolas G, Behin A, Bassez G, Leturcq F, Ben Yaou R, Mansencal N, Annane D, Lofaso F, Orlikowski D. Determinants of diaphragm inspiratory motion, diaphragm thickening, and its performance for predicting respiratory restrictive pattern in Duchenne muscular dystrophy. Muscle Nerve. 2021 Oct 07; doi: 10.1002/mus.27432. Epub 2021 Oct 07. PMID: 34618930.
Copy Download .nbib Format: NLM
Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease.

International journal of molecular sciences

Bekkers M, Stojkovic B, Kaiko GE.
PMID: 34681902
Int J Mol Sci. 2021 Oct 18;22(20). doi: 10.3390/ijms222011243.

The intestinal microbiota is a complex community that consists of an ecosystem with a dynamic interplay between bacteria, fungi, archaea, and viruses. Recent advances in model systems have revealed that the gut microbiome is critical for maintaining homeostasis through...

Cite
Bekkers M, Stojkovic B, Kaiko GE. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. Int J Mol Sci. 2021;22(20)doi: 10.3390/ijms222011243.
Bekkers, M., Stojkovic, B., & Kaiko, G. E. (2021). Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. International journal of molecular sciences, 22(20), . https://doi.org/10.3390/ijms222011243
Bekkers, Matthijs, et al. "Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease." International journal of molecular sciences vol. 22,20 (2021). doi: https://doi.org/10.3390/ijms222011243
Bekkers M, Stojkovic B, Kaiko GE. Mining the Microbiome and Microbiota-Derived Molecules in Inflammatory Bowel Disease. Int J Mol Sci. 2021 Oct 18;22(20). doi: 10.3390/ijms222011243. PMID: 34681902; PMCID: PMC8540913.
Copy Download .nbib Format: NLM
TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target.

Blood

Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, Phillips EH, Burley TA, Mitchell S, Devereux S, Fegan CD, Jones CI, Johnston R, Chevassut T, Schulz R, Seiffert M, Agathanggelou A, Oldreive C, Davies N, Stankovic T, Liloglou T, Pepper C, Pepper AGS.
PMID: 33512408
Blood. 2021 Jun 03;137(22):3064-3078. doi: 10.1182/blood.2020005964.

Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9) is a promising candidate that is activated by unmethylated...

Cite
Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021;137(22):3064-3078doi: 10.1182/blood.2020005964.
Kennedy, E., Coulter, E., Halliwell, E., Profitos-Peleja, N., Walsby, E., Clark, B., Phillips, E. H., Burley, T. A., Mitchell, S., Devereux, S., Fegan, C. D., Jones, C. I., Johnston, R., Chevassut, T., Schulz, R., Seiffert, M., Agathanggelou, A., Oldreive, C., Davies, N., Stankovic, T., Liloglou, T., Pepper, C., & Pepper, A. G. S. (2021). TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood, 137(22), 3064-3078. https://doi.org/10.1182/blood.2020005964
Kennedy, Emma, et al. "TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target." Blood vol. 137,22 (2021): 3064-3078. doi: https://doi.org/10.1182/blood.2020005964
Kennedy E, Coulter E, Halliwell E, Profitos-Peleja N, Walsby E, Clark B, Phillips EH, Burley TA, Mitchell S, Devereux S, Fegan CD, Jones CI, Johnston R, Chevassut T, Schulz R, Seiffert M, Agathanggelou A, Oldreive C, Davies N, Stankovic T, Liloglou T, Pepper C, Pepper AGS. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021 Jun 03;137(22):3064-3078. doi: 10.1182/blood.2020005964. PMID: 33512408; PMCID: PMC8176769.
Copy Download .nbib Format: NLM
Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction.

British journal of biomedical science

Burger AL, Stojkovic S, Diedrich A, Wojta J, Demyanets S, Pezawas T.
PMID: 33502288
Br J Biomed Sci. 2021 Oct;78(4):195-200. doi: 10.1080/09674845.2021.1883257. Epub 2021 Feb 26.

No abstract available.

Cite
Burger AL, Stojkovic S, Diedrich A, et al. Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction. Br J Biomed Sci. 2021;78(4):195-200doi: 10.1080/09674845.2021.1883257.
Burger, A. L., Stojkovic, S., Diedrich, A., Wojta, J., Demyanets, S., & Pezawas, T. (2021). Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction. British journal of biomedical science, 78(4), 195-200. https://doi.org/10.1080/09674845.2021.1883257
Burger, A L, et al. "Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction." British journal of biomedical science vol. 78,4 (2021): 195-200. doi: https://doi.org/10.1080/09674845.2021.1883257
Burger AL, Stojkovic S, Diedrich A, Wojta J, Demyanets S, Pezawas T. Cardiac biomarkers for risk stratification of arrhythmic death in patients with heart failure and reduced ejection fraction. Br J Biomed Sci. 2021 Oct;78(4):195-200. doi: 10.1080/09674845.2021.1883257. Epub 2021 Feb 26. PMID: 33502288.
Copy Download .nbib Format: NLM
Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders.

Current drug metabolism

Lalosevic MS, Lalosevic J, Stjepanovic M, Stojanovic M, Stojkovic M.
PMID: 33198613
Curr Drug Metab. 2021;22(2):99-107. doi: 10.2174/1389200221999201116143109.

Cutaneous manifestations due to drugs used in the treatment of gastrointestinal disorders are multiple and common. Adequate diagnosis is of great importance, bearing in mind that the therapeutic regimen depends on its diagnosis. In this review, we provided an...

Cite
Lalosevic MS, Lalosevic J, Stjepanovic M, et al. Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders. Curr Drug Metab. 2021;22(2):99-107doi: 10.2174/1389200221999201116143109.
Lalosevic, M. S., Lalosevic, J., Stjepanovic, M., Stojanovic, M., & Stojkovic, M. (2021). Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders. Current drug metabolism, 22(2), 99-107. https://doi.org/10.2174/1389200221999201116143109
Lalosevic, Milica S, et al. "Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders." Current drug metabolism vol. 22,2 (2021): 99-107. doi: https://doi.org/10.2174/1389200221999201116143109
Lalosevic MS, Lalosevic J, Stjepanovic M, Stojanovic M, Stojkovic M. Drug Induced Cutaneous Manifestations due to Treatment of Gastrointestinal Disorders. Curr Drug Metab. 2021;22(2):99-107. doi: 10.2174/1389200221999201116143109. PMID: 33198613.
Copy Download .nbib Format: NLM
Perineural invasion as a prognostic factor in patients with stage I-III rectal cancer - 5-year follow up.

World journal of gastrointestinal oncology

Stojkovic Lalosevic M, Milovanovic T, Micev M, Stojkovic M, Dragasevic S, Stulic M, Rankovic I, Dugalic V, Krivokapic Z, Pavlovic Markovic A.
PMID: 32461790
World J Gastrointest Oncol. 2020 May 15;12(5):592-600. doi: 10.4251/wjgo.v12.i5.592.

BACKGROUND: Rectal cancer (RC) is one of the most common diagnosed cancers, and one of the major causes of cancer-related death nowadays. Majority of the current guidelines rely on TNM classification regarding therapy regiments, however recent studies suggest that...

Cite
Stojkovic Lalosevic M, Milovanovic T, Micev M, et al. Perineural invasion as a prognostic factor in patients with stage I-III rectal cancer - 5-year follow up. World J Gastrointest Oncol. 2020;12(5):592-600doi: 10.4251/wjgo.v12.i5.592.
Stojkovic Lalosevic, M., Milovanovic, T., Micev, M., Stojkovic, M., Dragasevic, S., Stulic, M., Rankovic, I., Dugalic, V., Krivokapic, Z., & Pavlovic Markovic, A. (2020). Perineural invasion as a prognostic factor in patients with stage I-III rectal cancer - 5-year follow up. World journal of gastrointestinal oncology, 12(5), 592-600. https://doi.org/10.4251/wjgo.v12.i5.592
Stojkovic Lalosevic, Milica, et al. "Perineural invasion as a prognostic factor in patients with stage I-III rectal cancer - 5-year follow up." World journal of gastrointestinal oncology vol. 12,5 (2020): 592-600. doi: https://doi.org/10.4251/wjgo.v12.i5.592
Stojkovic Lalosevic M, Milovanovic T, Micev M, Stojkovic M, Dragasevic S, Stulic M, Rankovic I, Dugalic V, Krivokapic Z, Pavlovic Markovic A. Perineural invasion as a prognostic factor in patients with stage I-III rectal cancer - 5-year follow up. World J Gastrointest Oncol. 2020 May 15;12(5):592-600. doi: 10.4251/wjgo.v12.i5.592. PMID: 32461790; PMCID: PMC7235181.
Copy Download .nbib Format: NLM
Clinical manifestations in trisomy 9 mosaicism.

The Turkish journal of pediatrics

Pejcic L, Stankovic T, Ratkovic-Jankovic M, Vasic K, Nikolic I.
PMID: 31365211
Turk J Pediatr. 2018;60(6):729-734. doi: 10.24953/turkjped.2018.06.015.

Pejcic L, Stankovic T, Ratkovic-Jankovic M, Vasic K, Nikolic I. Clinical manifestations in trisomy 9 mosaicism. Turk J Pediatr 2018; 60: 729- 734. Trisomy 9 is a rare chromosome abnormality which can occur in a mosaic or nonmosaic state...

Cite
Pejcic L, Stankovic T, Ratkovic-Jankovic M, et al. Clinical manifestations in trisomy 9 mosaicism. Turk J Pediatr. 2018;60(6):729-734doi: 10.24953/turkjped.2018.06.015.
Pejcic, L., Stankovic, T., Ratkovic-Jankovic, M., Vasic, K., & Nikolic, I. (2018). Clinical manifestations in trisomy 9 mosaicism. The Turkish journal of pediatrics, 60(6), 729-734. https://doi.org/10.24953/turkjped.2018.06.015
Pejcic, Ljiljana, et al. "Clinical manifestations in trisomy 9 mosaicism." The Turkish journal of pediatrics vol. 60,6 (2018): 729-734. doi: https://doi.org/10.24953/turkjped.2018.06.015
Pejcic L, Stankovic T, Ratkovic-Jankovic M, Vasic K, Nikolic I. Clinical manifestations in trisomy 9 mosaicism. Turk J Pediatr. 2018;60(6):729-734. doi: 10.24953/turkjped.2018.06.015. PMID: 31365211.
Copy Download .nbib Format: NLM
Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with high risk of severe evolution.

Acta clinica Belgica

Sepulchre E, Pittie G, Stojkovic V, Haesbroek G, Crama Y, Schyns M, Paridaens H, de Marchin J, Degesves S, Biemar C, Boccar S, Senterre JM, Minon JM.
PMID: 32935644
Acta Clin Belg. 2020 Sep 16;1-7. doi: 10.1080/17843286.2020.1822078. Epub 2020 Sep 16.

BACKGROUND: The aim of this study was to identify early clinical and laboratory predictive factors of a severe coronavirus disease 2019 (COVID-19).METHODS: A retrospective study was conducted on adult patients hospitalized for COVID-19 in our hospital. Diagnosis was based...

Cite
Sepulchre E, Pittie G, Stojkovic V, et al. Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with high risk of severe evolution. Acta Clin Belg. 2020;1-7doi: 10.1080/17843286.2020.1822078.
Sepulchre, E., Pittie, G., Stojkovic, V., Haesbroek, G., Crama, Y., Schyns, M., Paridaens, H., de Marchin, J., Degesves, S., Biemar, C., Boccar, S., Senterre, J. M., & Minon, J. M. (2020). Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with high risk of severe evolution. Acta clinica Belgica, 1-7. https://doi.org/10.1080/17843286.2020.1822078
Sepulchre, Edith, et al. "Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with high risk of severe evolution." Acta clinica Belgica vol. (2020): 1-7. doi: https://doi.org/10.1080/17843286.2020.1822078
Sepulchre E, Pittie G, Stojkovic V, Haesbroek G, Crama Y, Schyns M, Paridaens H, de Marchin J, Degesves S, Biemar C, Boccar S, Senterre JM, Minon JM. Covid-19: contribution of clinical characteristics and laboratory features for early detection of patients with high risk of severe evolution. Acta Clin Belg. 2020 Sep 16;1-7. doi: 10.1080/17843286.2020.1822078. Epub 2020 Sep 16. PMID: 32935644.
Copy Download .nbib Format: NLM
Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease.

Molecular psychiatry

Filippi M, Basaia S, Sarasso E, Stojkovic T, Stankovic I, Fontana A, Tomic A, Piramide N, Stefanova E, Markovic V, Kostic VS, Agosta F.
PMID: 32409731
Mol Psychiatry. 2021 Sep;26(9):5429-5440. doi: 10.1038/s41380-020-0770-0. Epub 2020 May 14.

Longitudinal connectivity studies might guide our understanding of the underlying neurodegenerative processes. We report the results of a longitudinal study in patients at different stages of Parkinson's disease (PD), who performed motor and non-motor evaluations and serial resting state...

Cite
Filippi M, Basaia S, Sarasso E, et al. Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease. Mol Psychiatry. 2020;26(9):5429-5440doi: 10.1038/s41380-020-0770-0.
Filippi, M., Basaia, S., Sarasso, E., Stojkovic, T., Stankovic, I., Fontana, A., Tomic, A., Piramide, N., Stefanova, E., Markovic, V., Kostic, V. S., & Agosta, F. (2021). Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease. Molecular psychiatry, 26(9), 5429-5440. https://doi.org/10.1038/s41380-020-0770-0
Filippi, Massimo, et al. "Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease." Molecular psychiatry vol. 26,9 (2021): 5429-5440. doi: https://doi.org/10.1038/s41380-020-0770-0
Filippi M, Basaia S, Sarasso E, Stojkovic T, Stankovic I, Fontana A, Tomic A, Piramide N, Stefanova E, Markovic V, Kostic VS, Agosta F. Longitudinal brain connectivity changes and clinical evolution in Parkinson's disease. Mol Psychiatry. 2021 Sep;26(9):5429-5440. doi: 10.1038/s41380-020-0770-0. Epub 2020 May 14. PMID: 32409731.
Copy Download .nbib Format: NLM
Showing 25 to 36 of 230 entries